TLDR
-
Leap surges 58% as Winklevoss leads $58.9M PIPE, merging biotech and crypto.
-
Leap rockets 58% after $58.9M PIPE; Winklevoss backs biotech-crypto strategy.
-
Winklevoss Capital fuels Leap’s 58% rally with $58.9M biotech-crypto PIPE.
-
Leap rises 58% on $58.9M Winklevoss-led deal blending biotech and blockchain.
-
$58.9M PIPE ignites Leap’s biotech-crypto pivot; Winklevoss takes the helm.
Leap Therapeutics surged nearly 58% during early trading, reaching $0.8429 after announcing a $58.9 million PIPE financing deal.
The transaction, led by Winklevoss Capital, propelled buying interest as the stock later stabilized between $0.81 and $0.84. The company plans to use the new capital for both clinical advancements and digital asset strategy.
The PIPE offering includes over 95 million common shares or pre-funded warrants and more than 71 million common stock warrants. Each unit was priced at $0.61439, with warrants exercisable at $0.5335 per share. This pricing satisfies Nasdaq’s “Minimum Price” rule, aligning with regulatory compliance.
This new agreement marks a pivotal shift in Leap’s financial strategy, integrating crypto assets with its biotech development goals. Winklevoss Capital will not only supply funds but also offer guidance in implementing the digital treasury strategy. The financing aims to create long-term shareholder value while strengthening Leap’s clinical and financial footing.
Winklevoss Capital Brings Strategic Control and Board Influence
Leap Therapeutics will expand its board of directors to 12 members, enhancing governance flexibility. Winklevoss Capital gains the right to nominate two directors, one of whom will serve as chairperson. This inclusion reflects a deeper strategic partnership beyond financial support.
Winklevoss Capital’s involvement signals a move toward active portfolio management and governance at Leap. Their participation aims to bridge financial innovation with the company’s clinical ambitions. The collaboration combines biotech expertise and digital asset exposure, positioning Leap for unconventional growth pathways.
Legal representation for the transaction includes Morgan, Lewis & Bockius LLP for Leap and Cooley LLP for Winklevoss Capital. The securities will be offered under Regulation D and Section 4(a)(2) exemptions from the Securities Act of 1933. A resale registration statement is expected to follow for transparency and compliance.
Funding Supports Key Drug Programs Including ESMO-Featured Therapy
Leap will channel part of the funds into its therapeutic pipeline, particularly FL-501 and sirexatamab, two promising cancer drug candidates. Sirexatamab recently completed a Phase 2 trial in colorectal cancer and will be presented at the ESMO Congress 2025 in Berlin. This milestone underscores Leap’s commitment to clinical progress alongside financial innovation.
The trial’s inclusion in a Mini Oral Session highlights the clinical relevance of Leap’s drug development efforts. The company aims to maintain this momentum through targeted capital allocation from the PIPE deal. Development updates are expected as the company advances toward potential late-stage trials.
Parcrest serves as the placement agent for the offering, which is expected to close on or around October 8, 2025. Leap plans to provide further updates on its crypto treasury rollout shortly. The dual-track strategy combining biotech R&D and digital asset investment sets a bold new direction.
